Xilio Therapeutics Inc (XLO)
1.29
+0.21
(+19.44%)
USD |
NASDAQ |
May 20, 16:00
1.17
-0.12
(-9.30%)
After-Hours: 20:00
Xilio Therapeutics Free Cash Flow (Quarterly): -10.50M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -10.50M |
December 31, 2023 | -13.43M |
September 30, 2023 | -13.37M |
June 30, 2023 | -16.89M |
March 31, 2023 | -25.42M |
December 31, 2022 | -18.73M |
September 30, 2022 | -20.24M |
Date | Value |
---|---|
June 30, 2022 | -17.53M |
March 31, 2022 | -21.09M |
December 31, 2021 | -17.54M |
September 30, 2021 | -20.83M |
June 30, 2021 | -20.57M |
March 31, 2021 | -22.90M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-25.42M
Minimum
Mar 2023
-10.50M
Maximum
Mar 2024
-18.39M
Average
-18.73M
Median
Dec 2022
Free Cash Flow (Quarterly) Benchmarks
Gilead Sciences Inc | 2.114B |
FibroGen Inc | -59.32M |
Avalo Therapeutics Inc | -6.202M |
IGM Biosciences Inc | -44.90M |
AEON Biopharma Inc | -- |